![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
The Initial Phase I Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK3640254, a Next-Generation HIV Maturation Inhibitor, as Assessed in Healthy Subjects
|
|
|
20th International Workshop on Clinical Pharmacology of HIV, Hepatitis & Other Antiviral Drugs. May 14-16, 2019. Noordwijk, the Netherlands
Reported by Jules Levin
Samit R. Joshi,1 Disala Fernando,2 Stephanie Igwe,2 Litza McKenzie,3 Anu S. Krishnatry,4 Fiona Halliday,5 Joyce Zhan,4 Mark Johnson,6 Geraldine Ferron-Brady,4 Max Lataillade,1 Sherene Min,6 on behalf of the GSK3640254 Study Team
![0520191](../images/052019/052019-3/0520191.gif)
![0520192](../images/052019/052019-3/0520192.gif)
![0520193](../images/052019/052019-3/0520193.gif)
![0520194](../images/052019/052019-3/0520194.gif)
![0520195](../images/052019/052019-3/0520195.gif)
![0520196](../images/052019/052019-3/0520196.gif)
![0520197](../images/052019/052019-3/0520197.gif)
![0520198](../images/052019/052019-3/0520198.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|